MODIFICATION
A -- Statistical and Data Coordinating Center (SDDC) for Clinical Research in Infectious Diseases - Solicitation 1
- Notice Date
- 11/22/2013
- Notice Type
- Modification/Amendment
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Office of Acquisitions, 6700 B Rockledge Room 3214 MSC7612, Bethesda, Maryland, 20892-7612
- ZIP Code
- 20892-7612
- Solicitation Number
- RFP-NIAID-DMID-NIHAI2013180
- Response Due
- 1/31/2014 1:00:00 PM
- Archive Date
- 2/15/2014
- Point of Contact
- Frank Vidergar, Phone: 301-402-1490, Aileene Mitchell Ford, Phone: 301-496-7288
- E-Mail Address
-
vidergarf@niaid.nih.gov, aileene.mitchellford@nih.gov
(vidergarf@niaid.nih.gov, aileene.mitchellford@nih.gov)
- Small Business Set-Aside
- Total Small Business
- Description
- Attachments Solicitation Type of Requirement: Re-competition Introduction The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of Microbiology and Infectious Diseases (DMID), has a requirement for a Statistical and Data Coordinating Center (SDCC) for Clinical Research in Infectious Diseases, described below. Description Research supported and conducted by the NIAID, NIH, DHHS, strives to understand, treat and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten millions of human lives. The NIAID DMID supports extramural research to control and prevent diseases caused by virtually all infectious agents. This includes basic and applied research to develop and evaluate therapeutics, vaccines, medical devices and diagnostics, which are funded through a variety of research grants and contracts. The evaluation of new and improved vaccine, device and therapeutic candidates in clinical trials and clinical studies is an essential element of the efforts of DMID. Through an extensive network of grant and contract research programs, DMID supports a broad range of clinical research, including single-site and multi-center clinical research and Phase 0 through 4 clinical trials evaluating bacterial, viral and parasitic vaccines, therapeutics, and other biologics, drugs, medical devices, and approaches as preventive and therapeutic measures against infectious diseases in people of all ages and risk categories. Support is also provided for a variety of other studies. Examples include: targeted surveillance for pathogens of interest in study populations; evaluations of novel investigational product delivery systems; and reevaluation of current vaccine formulations, schedules and modes of delivery. Clinical trials and clinical studies are also supported to evaluate the safety and efficacy of vaccines, medical devices and therapeutics for a wide variety of emerging and re-emerging infectious diseases ( http://www.niaid.nih.gov/topics/emerging/Pages/list.aspx ), which includes NIAID Category A-C Priority Pathogens to meet critical public health needs. NIAID is conducting an acquisition for the establishment and management of a Statistical and Data Coordinating Center to support DMID's extramural clinical research programs through the provision of: statistical design and analysis expertise; computerized systems for the collection, storage, management, reporting and quality control of study data; assistance in the preparation of study-related materials; a system for the tracking of clinical specimens; data collection and management user training; clinical site capability assessment for data collection and management; project/site management; and, a data repository for completed DMID-sponsored clinical studies. This requirement will be conducted as a Total Small Business Set-Aside. It is anticipated that one (1) cost-reimbursement, Level-of-Effort type contract will be awarded for a one-year Base period and six (6), one-year term Option periods with the period of performance beginning on or about December 1, 2014. It is estimated that 41.40 Full-Time Equivalents (FTEs) per year, including subcontractor and consultant personnel, will be required. This information is furnished to potential offerors for information purposes only and is not to be considered restrictive for proposal purposes. In order to be eligible for award of a contract, registration under North American Industry Classification System (NAICS) code 541712--Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology) is required. The small business size standard is 500 employees. To register, go to https://www.sam.gov/portal/public/SAM/. Questions regarding this solicitation should be directed to only the primary or secondary points of contact whose information is provided in this solicitation. Contact with Government personnel other than the primary or secondary points of contact is strictly prohibited.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIAID/RFP-NIAID-DMID-NIHAI2013180/listing.html)
- Place of Performance
- Address: The place of performance is currently unknown., United States
- Record
- SN03239522-W 20131124/131122234010-a8230f2e19307ac0ad102d6de3317859 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |